Survival and treatment of stage IV renal cell carcinoma in academic vs non-academic medical centers

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

147

Figures (1-2)

Tables (1-4)

Sum=230

Publishing Process of This Article

Item

Count

Browse

Download

Sum=24

Jun 25, 2025 (publication date) through Apr 18, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Nephrol. Jun 25, 2025; 14(2): 103923
Published online Jun 25, 2025. doi: 10.5527/wjn.v14.i2.103923

Table 2 Demographic, socioeconomic, and clinical characteristics of patients with metastatic renal cell carcinoma, n (%)

Variable (n = 79367)	Academic facility (n = 30780)	Non-academic facility (n = 48587)	P value
Age [mean (SD)]	63.8 (10.9)	66.6 (11.4)	< 0.05
Distance travelled [mean (SD)]	57.6 (136)	23.8 (86.7)	< 0.05
Sex			0.511
Male	21428 (69.6)	32637 (67.2)
Female	9352 (30.4)	15950 (32.8)
Insurance status			< 0.05
Race			< 0.05
White	42600 (88.4)	25591 (84.1)
Black	4160 (8.6)	3473 (11.4)
Other	1441 (3.0)	1363 (4.5)
Race-missing data	739
Private insurance	11954 (40.7)	16790 (35.9)
Medicaid	2747 (9.4)	3120 (6.7)
Medicare	12744 (43.4)	25470 (54.5)
Other government	482 (1.6)	707 (1.5)
Insurance Status unknown	1418 (4.8)	653 (1.4)
Income class			< 0.05
< $38000	3666 (11.9)	5495 (11.3)
$38000-$47999	5422 (17.6)	7993 (16.5)
$48000-$62999	6032 (19.6)	10782 (22.2)
> $63000	9327 (30.3)	1317 (27.1)
Urban/Rural			< 0.05
Metro area greater than 1 million people	15886 (51.6)	21670 (44.6)
Metro area 250000–1 million	5856 (19.0)	10980 (22.6)
Metro area < 250000	9038 (29.4)	15937 (32.8)
Tumor size [mean (SD)]	481 (450)	469 (453)	< 0.05
Facility location			< 0.05
New England	2322 (4.8)	1496 (4.9)
Middle Atlantic	4540 (9.3)	6164 (20.0)
South Atlantic	10448 (21.5)	5796 (18.8)
East North Central	8959 (18.4)	4851 (15.8)
East South Central	3883 (8.0)	1758 (9.6)
West North Central	4211 (8.7)	2955 (12.3)
West South Central	5186 (10.7)	3793 (12.3)
Mountain	2189 (5.8)	859 (2.8)
Pacific	6219 (12.8)	3108 (10.1)
Regional lymph nodes positive	77.6 (39.4)	85.7 (32.2)	< 0.05
Charleson-deyo score			< 0.05
0	22077 (71.4)	32286 (66.4)
1	5638 (18.3)	10001 (20.6)
2	1784 (5.8)	3715 (7.6)
3	1281 (4.2)	2585 (5.3)

Citation: Weng B, Braaten M, Lehn J, Morrissey R, Asghar MS, Silberstein P, Abdul Jabbar AB, Mathews A, Tauseef A, Mirza M. Survival and treatment of stage IV renal cell carcinoma in academic vs non-academic medical centers. World J Nephrol 2025; 14(2): 103923
URL: https://www.wjgnet.com/2220-6124/full/v14/i2/103923.htm
DOI: https://dx.doi.org/10.5527/wjn.v14.i2.103923